Decoy Therapeutics Inc. (DCOY)
NASDAQ: DCOY · Real-Time Price · USD
8.63
+0.02 (0.23%)
Jun 3, 2026, 9:30 AM EDT - Market open
Decoy Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
11
Market Cap
4.59M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 1.84M | -3.39M | -64.84% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| 60 Degrees Pharmaceuticals | 1.31M |
| VivoSim Labs | 142.00K |
| Silo Pharma | 72.10K |
| Azitra | 7.50K |
| Pulmatrix | 3.00K |
DCOY News
- 2 hours ago - Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors - PRNewsWire
- 2 days ago - Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic - PRNewsWire
- 8 days ago - Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board - PRNewsWire
- 26 days ago - Decoy Therapeutics Quarterly report: Q1 2026 - Filings
- 5 weeks ago - Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston - PRNewsWire
- 7 weeks ago - Decoy Therapeutics Transcript: Status update - Transcripts
- 7 weeks ago - Decoy Therapeutics Press release: Status update - Filings
- 7 weeks ago - Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline - PRNewsWire